RxDoctor Payments Data

Chun Chen

Internal Medicine · Smithtown, NYNPI 1780881680

Payments from drug & device makers

$569in general payments, 2019–2025

Across 35 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$147
  • AstraZeneca$145
  • Merck$65
  • Amgen$54
  • Kowa Pharmaceuticals America, Inc.$48
  • Johnson & Johnson$37
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$52592%
  • Education$448%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$569 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$132,833
Medicare patients
154
Services billed
1,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$94,961
EliquisApixaban31$56,071
JanuviaSitagliptin Phosphate37$49,442
FarxigaDapagliflozin Propanediol39$47,487
JardianceEmpagliflozin17$28,580
XareltoRivaroxaban14$22,660
ProliaDenosumab13$21,631
Tresiba Flextouch U-100Insulin Degludec16$14,139
SymbicortBudesonide/Formoterol Fumarate12$5,854
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$3,322
Novolog FlexpenInsulin Aspart13$2,662
Rosuvastatin Calcium133$2,629
Nano 2nd Gen Pen NeedlePen Needle, Diabetic26$2,619
Metoprolol Succinate143$2,281
Losartan Potassium162$1,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$94,96145 claims
PfizerEliquis$19$56,07131 claims
AstraZenecaFarxiga, Symbicort$145$53,34151 claims
MerckJanuvia$65$49,44237 claims
Boehringer IngelheimJardiance$12$28,58017 claims
Johnson & JohnsonXarelto$37$22,66014 claims
AmgenProlia$54$21,63113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →